NCT07747688 Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
| NCT ID | NCT07747688 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Friendship Hospital |
| Condition | Early Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2026-05-08 |
| Primary Completion | 2027-05-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2026-05-08 with a primary completion date of 2027-05-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this retrospective observational cohort study is to describe the real-world clinicopathological characteristics, evolving treatment patterns, and long-term oncological outcomes of early gastric cancer (EGC) patients in China, utilizing a large prospective clinical database. The main questions it aims to answer are: How do different treatment modalities, including endoscopic resection, laparoscopic surgery, open surgery, and combined laparoscopic-endoscopic approaches, influence the long-term survival (Overall Survival and Disease-Free Survival) and recurrence patterns in Chinese EGC patients? What are the key clinicopathological factors affecting prognosis in this population? This study will retrospectively enroll approximately 5000 patients with histopathologically confirmed gastric adenocarcinoma staged as early gastric cancer (per AJCC 8th edition) from the information database of the National Clinical Research Center for Digestive Diseases. Researchers will systematically collect baseline demographics, treatment details, surgical complications, pathological staging, and longitudinal follow-up data (up to 10 years post-surgery) for all eligible patients. By comparing the short-term safety profiles and long-term survival benefits across different treatment groups and identifying risk factors for recurrence, this study aims to provide high-quality, China-specific evidence to guide standardized and individualized clinical decision-making for early gastric cancer.
Eligibility Criteria
Inclusion Criteria: * patients aged between 18 and 90 years; * preoperative endoscopic biopsy-confirmed gastric adenocarcinoma; * clinical stage early gastric (cT1NxM0) cancer according to the AJCC 8th edition TNM staging system; * patients who have signed a broad informed consent. * Received primary treatment (including endoscopic resection, laparoscopic surgery, open surgery, or combined laparoscopic-endoscopic approach) at Beijing Friendship Hospital. Exclusion Criteria: * pregnant or breastfeeding women; * Preoperative or intraoperative diagnosis remained indeterminate due to insufficient pathological or imaging evidence, such that the patient could not be clearly classified as early gastric cancer prior to treatment; * Critical clinical data were severely incomplete or missing； * Completely lost to follow-up with no available information to confirm survival status.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07747688 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Early Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07747688 currently recruiting?
Yes, NCT07747688 is actively recruiting participants. Contact the research team at zhengzhi@ccmu.edu.cn for enrollment information.
Where is the NCT07747688 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07747688 clinical trial?
NCT07747688 is sponsored by Beijing Friendship Hospital. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.